To correlate the observed inhibition of ROCK1/2 and MRCKα/β by the DJ4 analogs on cancer cell growth and determine the relative efficacy of each analog, melanoma (A375M), lung (A549), and breast cancer (MDA-MB-231) cells were treated for 48 h with multiple concentrations of each compound. The gene discussed is CDC42BPA; the disease is cancer.